Chinese pharma company execs face criminal charges for obstructing antitrust probe – sources
09 October 2019 - 12:00 am UTC
Executives from a local Chinese manufacturer of active pharmaceutical ingredients (API) in Shandong Province are facing criminal charges for obstructing an antitrust investigation, three sources familiar with the matter told PaRR.
More than a dozen senior executives from the company have been arrested or are wanted by the authorities over attacks on antitrust officials from the State Administration for Market Regulation (SAMR) earlier this year, the sources said.
The sources declined to name the company involved, which was being investigated for alleged abuse of dominance.
PaRR subscribers can read the full article on PaRR here.
Not a subscriber? PaRR delivers global intelligence on competition law. To read this article and more, apply for a free trial below.